Literature DB >> 9585203

Research toward vaccines against malaria.

L H Miller1, S L Hoffman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9585203     DOI： 10.1038/nm0598supp-520

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  36 in total

1.  The potential impact of integrated malaria transmission control on entomologic inoculation rate in highly endemic areas.

Authors:  G F Killeen; F E McKenzie; B D Foy; C Schieffelin; P F Billingsley; J C Beier
Journal:  Am J Trop Med Hyg       Date:  2000-05       Impact factor: 2.345

2.  HLA-A*01-restricted cytotoxic T-lymphocyte epitope from the Plasmodium falciparum circumsporozoite protein.

Authors:  A Kumar; S Kumar; T P Le; S Southwood; J Sidney; J Cohen; A Sette; S L Hoffman
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 3.  Genetics of mosquito vector competence.

Authors:  B T Beerntsen; A A James; B M Christensen
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 4.  Tropical medicine.

Authors:  H W Murray; J Pépin; T B Nutman; S L Hoffman; A A Mahmoud
Journal:  BMJ       Date:  2000-02-19

5.  Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.

Authors:  Markus S Mueller; Annabelle Renard; Francesca Boato; Denise Vogel; Martin Naegeli; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

6.  Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response.

Authors:  P V Lalitha; Lisa A Ware; Arnoldo Barbosa; Sheetij Dutta; J Kathleen Moch; J David Haynes; Bader B Fileta; Charles E White; David E Lanar
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  Prevention and treatment of vivax malaria.

Authors:  J Kevin Baird; Eli Schwartz; Stephen L Hoffman
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

8.  Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.

Authors:  Y P Shi; S E Hasnain; J B Sacci; B P Holloway; H Fujioka; N Kumar; R Wohlhueter; S L Hoffman; W E Collins; A A Lal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.